Myriad Genetics (MYGN) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Myriad Genetics

NasdaqGS•Healthcare•Diagnostics & Research

$3.19-0.04(-0.01%)Market closed

Market Cap

$301.46M

P/S

0.4x

P/B

1.0x

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

How this company scores

WeakMetricSide Score: 45/100

Grade capped at D — Interest coverage below 1× (-6.0x) — earnings cannot cover interest. Strongest: Profitability (14/25); weakest: Cash & Earnings Quality (7/25).

Profitability14/25

Growth10/25

Balance Sheet & Red Flags14/25

Cash & Earnings Quality7/25

Strengths

Long cash runwayLow leverageProfit converts from growth

Grade capped at D

Interest coverage below 1× (-6.0x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 0.4x5y range 0.4x – 4.1x

Currently below its 20-quarter median.

P/B · 1.0x5y range 1.0x – 3.4x

Currently below its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 5 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $301.46M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $806.60M
Q. Revenue: $190.70M
TTM EBITDA: $-48.40M
TTM Op. Income: $-98.60M
Q. Op. Income: $-38.90M
TTM Net Income: $-112.60M
Q. Net Income: $-43.20M
EPS: $-0.46
Shares Out.: $94.80M

$806.60M in TTM revenue declined 3.2% YoY, reaching $190.70M last quarter. TTM EBITDA of $-48.40M and TTM operating income of $-98.60M show growth is flowing through to the bottom line. However, net income is negative at $112.60M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is down 3% — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 66.6%
EBITDA Margin: -13.8%
Op. Margin: -20.4%
Net Margin: -22.7%

Op. margin of -20.4% is up 134.1% YoY — cost efficiency is improving. Net margin at -22.7% and gross margin of 66.6% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has fallen for 2 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 0.4x
P/B Ratio: 1.0x

P/S of 0.4x and P/B of 1.0x. P/S is low relative to typical market levels.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $638.90M
Cash: $115.20M
Long-Term Debt: $120.70M
Book Value: $303.90M
D/E Ratio: 0.4
Debt/EBITDA: N/A

With $638.90M in assets and $120.70M in long-term debt, D/E is 0.4and book value is $303.90M — a conservative capital structure with a cushion to weather downturns. Across the last 7 quarters, debt/equity has risen for 6 consecutive quarters — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-8.30M
TTM Free Cash Flow: $-7.30M
FCF Margin: -0.9%
FCF / Net Income: 0.1

TTM FCF of $-7.30M on $-8.30M in operating cash flow. The FCF / Net Income ratio of 0.1x means cash covers only part of net income — earnings quality needs attention. Across the last 8 quarters, free cash flow has risen for 4 consecutive quarters — an improving trend.